Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ORGANIZATION
ORGANIZATION
- JGA to Push for Changing Brand-Based Product Names to Generic Names
December 28, 2011
- JGA President Sawai Says Additional Price Cuts for Generics “In No Way Acceptable”
December 27, 2011
- FPMAJ, JPMA “Truly Regret” Additional Price Cuts for Long-Listed, Generic Drugs
December 27, 2011
- JPMA's Kawabe Says Additional Price Cut for Long-Listed Products is “Not a Rule”
December 22, 2011
- Cancer Patient Groups Submit Petition Asking for Elimination of Drug Lag
December 20, 2011
- Doctor Survey Shows AD at Top of Most Medically Significant Diseases in 2020
December 20, 2011
- GSK President Fauchet Appointed New Chairman, EFPIA Japan
December 20, 2011
- Mr Sawai of JGA Announces “Absolute Opposition” to Add’l Price Reduction for Generics
December 20, 2011
- JCQHC Calls Attention to Contraindication of Coadministration
December 19, 2011
- Drug Pricing Subcommittee President Bessho Calls for Correction in “Across-the-Board” Bundling
December 15, 2011
- Drug Expenditure Ratio Should Be Fixed: Professor Endo, Gakushuin University
December 15, 2011
- Industry Reps Call for 4-6 Year Extension of Trial for Premium for New Drug Development
December 15, 2011
- Share of Generics Virtually Unchanged at 23.2%: JGA Flash Report
December 14, 2011
- 129 Hospitals Stopped Providing Services in Ophthalmology Since 2008: JOA
December 13, 2011
- JMA Announces View on TPP Agreement on Website
December 12, 2011
- Osaka Bio Fund Chooses Tokyo Drug Discovery Venture as No. 3 Investment Project
December 9, 2011
- JACDS Engaged in Petition Drive to Prevent Ban on “Dispensing Point” Services
December 9, 2011
- Shortest Development, Review Periods for New Drugs in 2010: OPIR Report
December 8, 2011
- FBRI to Open Nation’s Biggest Manufacturing Facility for Investigational PET Drugs
December 7, 2011
- PSUR to Be Renamed PBRER: ICH
December 5, 2011
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…